Open access
Jul 2026
BL-918 as a Novel Neuroprotective Agent Targeting SMP30 in Parkinson’s Disease: A Therapeutic Evaluation
It is suggested that BL-918 could potentially modulate SMP30 at the functional protein level, and SwissADME and ProTox 3.0 characterized BL-918 as a viable therapeutic lead, outlining key pharmacokinetic targets for future optimization.
Hardi M. Makwana, S. S. Swain, B. Paital et al.
· Journal of Applied Pharmaceu... · 0 citations